PMID- 35666357
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221129
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 40
IP  - 6
DP  - 2022 Dec
TI  - A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and 
      validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains 
      relapse-free during the treatment of crizotinib: a case report.
PG  - 1350-1353
LID - 10.1007/s10637-022-01262-2 [doi]
AB  - In resected non-small cell lung cancer (NSCLC), ALK rearrangements are associated 
      with worse recurrence-free survival (RFS) than other driver genes. In addition, 
      the micropapillary pattern of NSCLC is associated with a poor prognosis. In 
      recent years, crizotinib tyrosine kinase inhibitors (TKIs) have been widely used 
      to treat patients with advanced NSCLC with ALK fusion. Patient survival outcomes 
      have become highly promising, reflecting the necessity of exploring the 
      application of ALK-TKIs in resected, early stage NSCLC with ALK rearrangements. A 
      60-year-old Chinese man was diagnosed with stage IIB lung adenocarcinoma 
      harboring a novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS 
      and validated by immunohistochemical staining (IHC) and fluorescence in situ 
      hybridization (FISH). Crizotinib (250 mg orally once daily) was administered to 
      the patient following surgery. The patient remained relapse-free after four 
      months and seven months. This report provided a valuable treatment plan for early 
      lung adenocarcinoma patients with high risks to prevent a postoperative 
      recurrence.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Wang, Chunguang
AU  - Wang C
AD  - Department of Thoracic Surgery, The second hospital of Jilin University, 
      Changchun, China.
FAU - Chen, Shu
AU  - Chen S
AD  - Department of Thoracic Surgery, The second hospital of Jilin University, 
      Changchun, China.
FAU - He, Qianru
AU  - He Q
AD  - The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
AD  - Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
FAU - Sun, Tingting
AU  - Sun T
AD  - The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
AD  - Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
FAU - Xu, Peiran
AU  - Xu P
AD  - Department of Thoracic Surgery, The second hospital of Jilin University, 
      Changchun, China. peiranxu8888@163.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220606
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - 0 (DNA, Intergenic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
EIN - Invest New Drugs. 2022 Aug 16;:. PMID: 35972630
MH  - Humans
MH  - Crizotinib/therapeutic use/pharmacology
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - DNA, Intergenic
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Immunohistochemistry
MH  - Neoplasm Recurrence, Local/drug therapy/genetics
MH  - *Adenocarcinoma of Lung/drug therapy/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Oncogene Proteins, Fusion/genetics
OTO - NOTNLM
OT  - Adjuvant crizotinib
OT  - Intergenic region ALK Fusion
OT  - Lung cancer
EDAT- 2022/06/07 06:00
MHDA- 2022/11/16 06:00
CRDT- 2022/06/06 15:33
PHST- 2022/04/01 00:00 [received]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/11/16 06:00 [medline]
PHST- 2022/06/06 15:33 [entrez]
AID - 10.1007/s10637-022-01262-2 [pii]
AID - 10.1007/s10637-022-01262-2 [doi]
PST - ppublish
SO  - Invest New Drugs. 2022 Dec;40(6):1350-1353. doi: 10.1007/s10637-022-01262-2. Epub 
      2022 Jun 6.